WHO ICTRP trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled…
PER-071-01 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-071-01 |
|---|---|
| Public title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerabllity of 24 Weeks of Nateglinide, Giibenciamide, or Placebo Treatment in Eiderly Type 2 Diabetes Mellitus Patients |
| Scientific title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerabllity of 24 Weeks of Nateglinide, Giibenciamide, or Placebo Treatment in Eiderly Type 2 Diabetes Mellitus Patients |
| Primary sponsor | NOVARTIS BIOSCIENSES PERU S.A., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Conditions | -E119 Non-insulin-dependent diabetes mellitus, without complications Non-insulin-dependent diabetes mellitus, without complications;E119;Non-insulin-dependent diabetes mellitus, without complications |
| Interventions | Group name:Group 1 Type of group;1 N° of participants:220 Intervention(s) description:Nateglinide active from 60 mg ac to 180 mg ac + Glibenclamide placebo; for 24 weeks Group name:Group 3 Type of group;2 N° of participants:110… |
| Registration date | Nov 22, 2001 |
| Target size | 0 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: